 LEEDS, England--BUSINESS WIRE--4D pharma plc AIM: DDD; NASDAQ: LBPS, a pharmaceutical company leading the development of Live Biotherapeutic products LBPs - a novel class of drug derived from the microbiome, today announces additional positive data from its completed Phase II trial of LBP Blautix in subjects with irritable bowel syndrome with constipation IBS-C or with diarrhea IBS-D. The data has been presented in a poster session at Digestive Disease Week DDW, on May 22, 2021, b 